Pituitary responsiveness to GH‐releasing hormone, GH‐releasing peptide‐2 and thyrotrophin‐releasing hormone in critical illness
The DOI matches its Crossref record.
Abstract
OBJECTIVE Protein hypercatabolism and preservation of fat depots are hallmarks of critical illness, which is associated with blunted pulsatile GH secretion and low circulating IGF‐I, TSH, T4 and T3. Repetitive TRH administration is known to reactivate the pituitary‐thyroid axis and to evoke paradoxical GH release in critical illness. We further explored the hypothalamic‐pituitary function in critical illness by examining the effects of GH‐releasing hormone (GHRH) and/or GH‐releasing peptide‐2 (GHRP‐2) and TRH administration. PATIENTS AND DESIGN Critically ill adults (n=40; mean age 55 years) received two i.v. boluses with a 6‐hour interval (0900 and 1500 h) within a cross‐over design. Patients were randomized to receive consecutively placebo and GHRP‐2 (n=10), GHRH and GHRP‐2 (n=10), GHRP‐2 and GHRH+GHRP‐2 (n=10), GHRH+GHRP‐2 and GHRH+GHRP‐2+TRH (n=10). The GHRH and GHRP‐2 doses were 1μg/kg and the TRH dose was 200μg. Blood samples were obtained before and 20, 40, 60 and 120 minutes after each injection. MEASUREMENTS Serum concentrations of GH, T4, T3, rT3, thyroid hormone binding globulin (TBG), IGF‐I, insulin and cortisol were measured by RIA; PRL and TSH concentrations were determined by IRMA. RESULTS Critically ill patients presented a striking GH response to GHRP‐2 (mean±SEM peak GH 51±9 μg/l in older patients and 102±2μg/l in younger patients; P=0.005 vs placebo). The mean GH response to GHRP‐2 was more than fourfold higher than to GHRH (P=0.007). In turn, the mean GH response to GHRH+GHRP‐2 was 2.5‐fold higher than to GHRP‐2 alone (P=0.01), indicating synergism. Adding TRH to the GHRH+GHRP‐2 combination slightly blunted this mean response by 18% (P=0.01). GHRP‐2 had no effect on serum TSH concentrations whereas both GHRH and GHRH+GHRP‐2 evoked an increase in peak TSH levels of 53 and 32% respectively. The addition of TRH further increased this TSH response < ninefold (P=0.005), elicited a 60% rise in serum T3 (P=0.01) and an 18% increase in T4 (P=0.005) levels, without altering rT3 or TBG levels. GHRH and/or GHRP‐2 induced a small increase in serum PRL levels. The addition of TRH magnified the PRL response 2.4‐fold (P=0.007). GHRP‐2 increased basal serum cortisol levels (531±29nmol/l) by 35% (P=0.02); GHRH provoked no additional response, but adding TRH further increased the cortisol response by 20% (P=0.05). CONCLUSIONS The specific character of hypothalamic‐pituitary function in critical illness is herewith extended to the responsiveness to GHRH and/or GHRP‐2 and TRH. The observation of striking bursts of GH secretion elicited by GHRP‐2 and particularly by GHRH+GHRP‐2 in patients with low spontaneous GH peaks opens the possibility of therapeutic perspectives for GH secretagogues in critical care medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
van der Lely, A. J., Tschöp, M., Heiman, M. L., & Ghigo, E. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0029 · Cited by 1,187
Thyroid function in critically ill patients
Fliers, E., Bianco, A. C., Langouche, L., & Boelen, A. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00225-9 · Cited by 441
Acute and Prolonged Critical Illness as Different Neuroendocrine Paradigms1
Van den Berghe, G., de Zegher, F., & Bouillon, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4763 · Cited by 342
Self-citationNovel insights into the neuroendocrinology of critical illness
Van den Berghe, G. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430001 · Cited by 257
Thyroid axis function and dysfunction in critical illness
Mebis, L., & Van den Berghe, G. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.03.002 · Cited by 99
Metadata
- Authors
- Van den Berghe, G., De Zegher, F., Bowers, C. Y., Wouters, P., Muller, P., Soetens, F., Vlasselaers, D., Schetz, M., Verwaest, C., Lauwers, P., & Bouillon, R.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1996-09
- Volume
- 45
- Issue
- 3
- Pages
- 341-351
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2062659760
- Cited by
- 74
- References
- 0
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pituitary responsiveness to GH‐releasing hormone, GH‐releasing peptide‐2 and thyrotrophin‐releasing hormone in critical illness. https://app.cochat.ai/papers/10.1046/j.1365-2265.1996.00805.x
- The paper
- Van den Berghe, G., De Zegher, F., Bowers, C. Y., Wouters, P., Muller, P., Soetens, F., Vlasselaers, D., Schetz, M., Verwaest, C., Lauwers, P., & Bouillon, R. (1996). Pituitary responsiveness to GH‐releasing hormone, GH‐releasing peptide‐2 and thyrotrophin‐releasing hormone in critical illness. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1996.00805.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.